Deepbridge Capital appoints Head of Life Sciences

Tax-efficient investment specialist Deepbridge Capital has today (26 January 2016) announced the appointment of Savvas Neophytou as partner and Head of Life Sciences.

With a PhD in Biomedical Science from the University of Nottingham, Neophytou joins Deepbridge to head up their Life Sciences proposition.  Previously he spent fifteen years working within both the bio-life sciences sector and corporate finance; including roles with the likes of JP Morgan, Bear Stearns and Panmure Gordon.

In 2015 Deepbridge launched the Deepbridge Life Sciences SEIS, a portfolio approach to investing in early stage life sciences businesses, and is currently developing additional opportunities for investors to access potentially exciting opportunities within biopharmaceuticals, biotechnology and medical technology.  Savvas Neophytou will lead the Deepbridge investment decisions within this sector.

The Deepbridge Life Sciences SEIS is seeking to raise £1.5m and closes on Thursday 24th March 2016.

Ian Warwick, Managing Partner at Deepbridge Capital, commented:

“I am delighted to be able to welcome Savvas to the growing Deepbridge team.  With the eminent Professor Chris Wood being a Partner at Deepbridge, we have been developing our Life Sciences proposition for some time, prior to launching the Deepbridge Life Sciences SEIS in 2015. In order that we can best manage the companies within this portfolio, and identify new opportunities for investors within this growing sector, it was important for us to create this new role and bring in an individual with experience of financing biomedical companies.  Savvas has a unique track record and is the perfect fit for us to provide investors with credible investment opportunities in this fast-paced sector.

“Deepbridge continues to grow and we are pleased with the feedback we receive from advisers and investors alike that they appreciate our commercial and transparent approach.”


Dr Savvas Neophytou is Partner and Head of Life Sciences at Deepbridge Capital LLP